Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP

被引:84
作者
Gu, YP [1 ]
Fujioka, H [1 ]
Mishra, RS [1 ]
Li, RL [1 ]
Singh, N [1 ]
机构
[1] Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA
关键词
D O I
10.1074/jbc.M104345200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In infectious and familial prion disorders, neurodegeneration is often seen without obvious deposits of the scrapie prion protein (PrPSc), the principal cause of neuronal death in prion disorders. In such cases, neurotoxicity must be mediated by alternative pathways of cell death. One such pathway is through a transmembrane form of PrP. We have investigated the relationship between intracellular accumulation of prion protein aggregates and the consequent up-regulation of transmembrane prion protein in a cell model. Here, we report that exposure of neuroblastoma cells to the prion peptide 106-126 catalyzes the aggregation of cellular prion protein to a weakly proteinase K-resistant form and induces the synthesis of transmembrane prion protein, the proposed mediator of neurotoxicity in certain prion disorders. The N terminus of newly synthesized transmembrane prion protein is cleaved spontaneously on the cytosolic face of the endoplasmic reticulum, and the truncated C-terminal fragment accumulates on the cell surface. Our results suggest that neurotoxicity in prion disorders is mediated by a complex pathway involving transmembrane prion protein and not by deposits of aggregated and proteinase K-resistant PrP alone.
引用
收藏
页码:2275 / 2286
页数:12
相关论文
共 38 条
[1]   PrPSc-like prion protein peptide inhibits the function of cellular prion protein [J].
Brown, DR .
BIOCHEMICAL JOURNAL, 2000, 352 :511-518
[2]   HUMAN SPONGIFORM ENCEPHALOPATHY - THE NATIONAL-INSTITUTES-OF-HEALTH SERIES OF 300 CASES OF EXPERIMENTALLY TRANSMITTED DISEASE [J].
BROWN, P ;
GIBBS, CJ ;
RODGERSJOHNSON, P ;
ASHER, DM ;
SULIMA, MP ;
BACOTE, A ;
GOLDFARB, LG ;
GAJDUSEK, DC .
ANNALS OF NEUROLOGY, 1994, 35 (05) :513-529
[3]   Transmissible spongiform encephalopathies, amyloidoses and yeast prions: Common threads? [J].
Caughey, B .
NATURE MEDICINE, 2000, 6 (07) :751-754
[4]   Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides [J].
Chabry, J ;
Caughey, B ;
Chesebro, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (21) :13203-13207
[5]   TRUNCATED FORMS OF THE HUMAN PRION PROTEIN IN NORMAL BRAIN AND IN PRION DISEASES [J].
CHEN, SG ;
TEPLOW, DB ;
PARCHI, P ;
TELLER, JK ;
GAMBETTI, P ;
AUTILIOGAMBETTI, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (32) :19173-19180
[6]   Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid β-peptide by microglial cells [J].
Chung, HY ;
Brazil, MI ;
Soe, TT ;
Maxfield, FR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32301-32308
[7]   Pathologic conformations of prion proteins [J].
Cohen, FE ;
Prusiner, SB .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :793-+
[8]   Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation [J].
Doh-Ura, K ;
Iwaki, T ;
Caughey, B .
JOURNAL OF VIROLOGY, 2000, 74 (10) :4894-4897
[9]   In vivo cytotoxicity of the prion protein fragment 106-126 [J].
Ettaiche, M ;
Pichot, R ;
Vincent, JP ;
Chabry, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (47) :36487-36490
[10]   Submicroscopic immunodetection of PrP in the brain of a patient with a new-variant of Creutzfeldt-Jakob disease [J].
Grigoriev, V ;
Escaig-Haye, F ;
Streichenberger, N ;
Kopp, N ;
Langeveld, J ;
Brown, P ;
Fournier, JG .
NEUROSCIENCE LETTERS, 1999, 264 (1-3) :57-60